AusperBio
PrivateLast Round
Series C
Aug 27, 2026
Total Funding Raised
$356.7M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
AusperBio operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series C round in August 2026.
AusperBio is a biopharmaceutical company that develops targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B and other liver diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AusperBio Comparables
Compare AusperBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mirum Pharmaceuticals | 84% | |
| Arbutus Biopharma Corp | 81% | |
| Ionis Pharmaceuticals, Inc. | 79% |
For institutional investors. Book with your work email.
AusperBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 27, 2026 | ||||
| Series B Extension | Sep 21, 2025 | ||||
| Series B Extension | May 28, 2025 | ||||
| Series B | Dec 26, 2024 | ||||
| Series A | Jul 14, 2024 | ||||
Seed | Nov 7, 2023 |
For institutional investors. Book with your work email.
AusperBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Series B Extension, Series B |
| RA Capital Management | Series C |
| Genesis Capital | Series B Extension |
| YuanBio Venture Capital | Series B Extension, Series B, Series A, Series C |
| Genesis Capital | Series B Extension, Series A |
| Sherpa Capital | Series B Extension, Series B, Series C |
| Sherpa Capital | Series B Extension, Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 27, 2026
$120M round with participation from CDH Investments and Hankang Capital.
- Jul 26, 2026
Monthly visitors increased 168% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 7, 2026
AusperBio Therapeutics, Inc. presents two late-breaking oral presentations on long-term follow-up data from AHB-137 treatment for chronic hepatitis B at The Liver Meeting(R) 2026 in Colorado on Nov 5th-9th '26.
- is_developingAug 28, 2026
AusperBio Therapeutics, Inc. is developing combination regimens that pair multiple therapeutic mechanisms to pursue a functional cure for hepatitis B in California as of Aug '26.
For institutional investors. Book with your work email.
AusperBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AusperBio's valuation, stock price, and market status.
Is AusperBio a public or private company?
AusperBio is a private company.
What is the current stock price of AusperBio?
AusperBio is a private company, so its shares have no public market price. Caplight tracks AusperBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AusperBio worth (valuation)?
Valuation information for AusperBio is not publicly available.
Can I buy AusperBio stock?
AusperBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AusperBio's last funding round?
AusperBio's most recent funding round was Series C on August 27, 2026.
Who are the main investors in AusperBio?
Key investors in AusperBio include Hankang Capital, Qiming Venture Partners.
Will AusperBio IPO soon?
No public IPO plans have been announced for AusperBio.
How can I track AusperBio secondary market activity?
Caplight tracks bids, offers, and trades in AusperBio's shares on secondary markets.